A deal announced on Monday with the pharmaceutical company GlaxoSmithKline (GSK) will manufacture up to 60 million doses of the Novavax vaccine. The vaccine is already being produced at a Fujifilm facility in Stockton-on-Tees, though the UK regulator has yet to approve the jab. What are the side effects of the Novavax vaccine?
President and Chief Executive Officer for Novavax said: “With today’s results from our UK Phase three and South Africa Phase 2b clinical trials, we have now reported data on our COVID-19 vaccine from Phase 1, 2 and 3 trials involving over 20,000 participants.
“In addition, our PREVENT-19 US and Mexico clinical trial has randomised over 16,000 participants toward our enrolment goal of 30,000. NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against COVID-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants.”
He continued: “NVX-CoV2373 has the potential to play an important role in solving this global public health crisis.
“We look forward to continuing to work with our partners, collaborators, investigators and regulators around the world to make the vaccine available as quickly as possible.”
REVEALED: Who ACTUALLY paid for the AztraZeneca vaccine [INSIGHT]
How much AstraZeneca vaccine is made in the UK? [INSIGHT]
High blood pressure: Foods to avoid [ADVICE]
Initial side effects from the Novovax vaccine include:
- High fever
The Novavax coronavirus vaccine is nearly 90 percent effective at preventing COVID-19.
Though the vaccine worked against all variants, it was less effective at preventing infections caused by the B.1.351 variant dominating in South Africa. Still, the vaccine, which produces a robust immune response, was effective at preventing severe cases of COVID-19.
Novavax is already working on a new vaccine that will target the new variant and expects to start testing it in a few months.